Adell Harriman & Carpenter Inc. Purchases 45,578 Shares of Pfizer Inc. $PFE

Adell Harriman & Carpenter Inc. lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 21.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 254,889 shares of the biopharmaceutical company’s stock after acquiring an additional 45,578 shares during the quarter. Adell Harriman & Carpenter Inc.’s holdings in Pfizer were worth $6,495,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of the business. Fiduciary Alliance LLC increased its position in shares of Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock valued at $3,701,000 after purchasing an additional 46,043 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in Pfizer in the third quarter worth approximately $3,019,000. Vista Investment Partners LLC grew its position in Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock valued at $1,774,000 after acquiring an additional 48,900 shares during the last quarter. Money Concepts Capital Corp lifted its holdings in shares of Pfizer by 29.9% in the 3rd quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after acquiring an additional 57,188 shares during the last quarter. Finally, Generali Investments CEE investicni spolecnost a.s. boosted its stake in shares of Pfizer by 76.4% in the 3rd quarter. Generali Investments CEE investicni spolecnost a.s. now owns 109,269 shares of the biopharmaceutical company’s stock valued at $2,784,000 after purchasing an additional 47,319 shares in the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Q4 beat on both EPS and revenue — Pfizer reported $0.66 EPS vs. $0.57 expected and revenue of $17.56B vs. ~$16.9B consensus, showing resilient demand for older drugs like Eliquis that helped offset COVID declines. Reuters: Pfizer beats fourth-quarter profit estimates
• Positive Sentiment: Obesity drug shows promise — Phase 2b data for PF’3944 (MET‑097i) showed up to ~12% weight loss with monthly dosing, supporting Pfizer’s strategy to build an obesity franchise and reduce reliance on COVID sales. BusinessWire: Phase 2b obesity trial results
• Neutral Sentiment: Company reaffirmed 2026 guidance — Pfizer reiterated its modest outlook (under $3 EPS) and reiterated strategic shift post‑Covid; that reduces uncertainty about management’s targets but signals limited near‑term upside. BusinessWire: Press release
• Neutral Sentiment: Analyst stance mixed — some firms (e.g., Goldman Sachs) maintain neutral ratings citing margin pressure and patent risks, keeping expectations tempered. InsiderMonkey: Goldman Sachs note
• Negative Sentiment: Profit and revenue headwinds flagged — management flagged an expected profit decline and analysts note a ~$1.5B near‑term hit from patent cliffs and lower COVID product demand, weighing on valuation. Seeking Alpha: revenue decline / patent cliff note
• Negative Sentiment: Safety and differentiation questions around the obesity drug — some coverage raised questions about side effects and whether monthly dosing will compete with established weekly GLP‑1 drugs (e.g., Lilly’s Zepbound), muting investor enthusiasm. MSN: safety questions
• Negative Sentiment: Vaccines and Covid sales continue to drag — ongoing declines in Covid vaccine/antiviral revenue are pressuring top‑line growth despite gains elsewhere. FT: vaccines weigh on sales

Pfizer Price Performance

Shares of Pfizer stock opened at $25.77 on Wednesday. The business has a 50 day moving average of $25.54 and a 200 day moving average of $25.06. Pfizer Inc. has a 52 week low of $20.92 and a 52 week high of $27.69. The company has a market cap of $146.53 billion, a PE ratio of 14.98 and a beta of 0.47. The company has a quick ratio of 0.97, a current ratio of 1.28 and a debt-to-equity ratio of 0.62.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 15.65% and a return on equity of 20.17%. The company had revenue of $17.56 billion during the quarter, compared to the consensus estimate of $16.93 billion. During the same period in the prior year, the firm earned $0.63 earnings per share. Pfizer’s revenue was down 1.2% on a year-over-year basis. As a group, equities research analysts forecast that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Stockholders of record on Friday, January 23rd will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.7%. The ex-dividend date is Friday, January 23rd. Pfizer’s dividend payout ratio (DPR) is presently 100.00%.

Wall Street Analysts Forecast Growth

Several analysts have weighed in on the stock. Morgan Stanley lowered their price target on shares of Pfizer from $32.00 to $28.00 and set an “equal weight” rating for the company in a research note on Friday, December 12th. The Goldman Sachs Group reissued a “neutral” rating and issued a $26.00 target price on shares of Pfizer in a research note on Wednesday, November 5th. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 price target on the stock. Sanford C. Bernstein reiterated a “market perform” rating and issued a $30.00 price objective on shares of Pfizer in a research report on Friday, October 31st. Finally, Zacks Research cut shares of Pfizer from a “hold” rating to a “strong sell” rating in a report on Monday, January 26th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, twelve have given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of “Hold” and an average target price of $28.06.

Pfizer Company Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.